Market cap
₹1,386 Cr
Recently Viewed
Clear AllNSE: JAGSNPHARM | BSE: 507789
₹205.55
₹1.88
(0.92%)
As on 28-Apr-2026IST
Market cap
₹1,386 Cr
Revenue (TTM)
₹287 Cr
P/E Ratio
32.2
P/B Ratio
5
Div. Yield
1.9 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹43 Cr
ROE
28.5 %
ROCE
33.1 %
Industry P/E
29.53
EV/EBITDA
18.3
Debt to Equity
0
Book Value
₹41.1
EPS
₹6.7
Face value
2
Shares outstanding
67,139,150
CFO
₹219.26 Cr
EBITDA
₹176.72 Cr
Net Profit
₹159.11 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Jagsonpal Pharma
| 6.7 | 11.3 | 25.5 | -14.7 | 14.8 | 39.6 | 30.7 |
|
BSE Healthcare
| 2.6 | 5.0 | 8.0 | 6.4 | 25.0 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Jagsonpal Pharma
| -25.9 | 55.1 | 4.3 | 108.4 | 122.1 | 178.9 | -18.4 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
No Review & Analysis are available.
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of... gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. It serves health care professionals and government institutions. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, India. Read more
Incorporated
1978
Chairman
Harsha Raghavan
Managing Director
Manish Gupta
Group
Jagsonpal
Headquarters
New Delhi, Delhi
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsCorporate Action-Board approves Dividend
27-Apr-2026Corporate Action-Board to consider Dividend
27-Apr-2026No News & Announcements are available.
The share price of Jagsonpal Pharmaceuticals Ltd is ₹205.55 (NSE) and ₹206.40 (BSE) as of 28-Apr-2026 IST. Jagsonpal Pharmaceuticals Ltd has given a return of 14.78% in the last 3 years.
The P/E ratio of Jagsonpal Pharmaceuticals Ltd is 32.17 times as on 28-Apr-2026, a 9 premium to its peers’ median range of 29.53 times.
The P/B ratio of Jagsonpal Pharmaceuticals Ltd is 5.02 times as on 28-Apr-2026, a 10 premium to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
25.90
|
6.58
|
|
2024
|
13.17
|
4.34
|
|
2023
|
11.37
|
5.06
|
|
2022
|
17.43
|
6.19
|
|
2021
|
4.89
|
1.83
|
The 52-week high and low of Jagsonpal Pharmaceuticals Ltd are Rs 301.65 and Rs 155.00 as of 28-Apr-2026.
Jagsonpal Pharmaceuticals Ltd has a market capitalisation of ₹ 1,386 Cr as on 28-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Jagsonpal Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.